Gilead Sciences, Inc. (GILD) Reports Advances in HIV Treatment with Phase 2/3 Clinical Trial Update

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio. Bridgewater Associates holds over $56 million worth of shares of GILD, which represents 0.26% of its portfolio.

On June 26, 2025, Gilead Sciences, Inc. (NASDAQ:GILD) announced the development of its ongoing Phase 2/3 clinical trial that is expected to treat HIV in pediatric patients. The study began in January 2014. It is focused on evaluating the safety, dosage, and effectiveness of cobicistat-boosted Atazanavir (ATV/co), cobicistat-boosted Darunavir (DRV/co), and Emtricitabine/Tenofovir Alafenamide (F/TAF) in participants with virologically suppressed HIV-1.

This development highlights the company’s continued commitment to advancing antiretroviral therapies for all age groups. Given the limited number of competitors in the pediatric HIV market, this progress is expected to strengthen Gilead Sciences, Inc.’s (NASDAQ:GILD) market position and boost investors’ confidence.

Gilead Sciences, Inc. (NASDAQ:GILD), a U.S.-based biopharmaceutical company, researches and develops antiviral drugs for patients with HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. GILD is among the list of cheap stocks to buy.

While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Disclosure: None.